Skip to content

Depreciation at other companies

AbbVie logo
AbbVieABBV
Vor Biopharma logo
Vor BiopharmaVOR
Zymeworks logo
ZymeworksZYME
Apogee Therapeutics, Inc. logo
Apogee Therapeutics, Inc.APGE
Dianthus Therapeutics logo
Dianthus TherapeuticsDNTH
Immunovant, Inc. logo
Immunovant, Inc.IMVT

Other financials

Income statement

See full
Revenue-
Operating income-$15.5M-8.0%
Net income-$14.8M-7.8%
EPS (diluted)-$0.13+51.9%

Balance sheet

See full
Cash & equivalents$90.4M+48.5%
Total debt$2.9M-9.5%
Total equity$95.8M+41.8%
Total assets$102.1M+32.3%

Cash flow

See full
Operating cash flow-$13.4M-11.6%
CapEx$63.0K
Free cash flow-$13.5M-12.1%

Valuation

See full
Market cap$564.45M+1,131%
Enterprise value$476.92M-4,119%
P/S564.5×+554×

Profitability

See full
Operating margin-5,266.4%-9,520pp
Net margin-4,987.4%-8,966pp
FCF margin-4,140.8%-7,144pp

Returns & leverage

See full
Return on equity-61%-8.0pp
Debt / equity0.0×
Current ratio22.1×+13.0×

Where this comes from

Reported directly by Shattuck Labs, Inc. in its filing.

Tagged under the XBRL concept us-gaap:Depreciation.

The official record: Shattuck Labs, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Shattuck Labs, Inc.'s depreciation.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Shattuck Labs, Inc.'s depreciation?
Shattuck Labs, Inc. (STTK) reported depreciation of $891K in Q1 2026.
How has Shattuck Labs, Inc.'s depreciation changed year-over-year?
Shattuck Labs, Inc.'s depreciation decreased by 4.8% year-over-year, from $936K to $891K.
What is the long-term trend for Shattuck Labs, Inc.'s depreciation?
Over 4 years (2021 to 2025), Shattuck Labs, Inc.'s depreciation has grown at a 27.9% compound annual growth rate (CAGR), from $1.38M to $3.69M.